Christina Chambers
Concepts (668)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications | 61 | 2026 | 592 | 11.050 |
Why?
| | Fetal Alcohol Spectrum Disorders | 40 | 2024 | 70 | 10.620 |
Why?
| | Pregnancy Outcome | 39 | 2026 | 476 | 7.490 |
Why?
| | Prenatal Exposure Delayed Effects | 53 | 2026 | 675 | 7.420 |
Why?
| | Milk, Human | 21 | 2025 | 172 | 6.850 |
Why?
| | Pregnancy | 199 | 2026 | 7191 | 6.550 |
Why?
| | Premature Birth | 36 | 2026 | 380 | 5.030 |
Why?
| | Breast Feeding | 24 | 2025 | 448 | 4.700 |
Why?
| | Abnormalities, Drug-Induced | 18 | 2026 | 32 | 3.870 |
Why?
| | Rheumatic Diseases | 13 | 2025 | 97 | 3.620 |
Why?
| | Alcohol Drinking | 29 | 2026 | 826 | 3.620 |
Why?
| | Antidepressive Agents | 11 | 2025 | 248 | 3.100 |
Why?
| | Congenital Abnormalities | 11 | 2024 | 104 | 2.810 |
Why?
| | Lactation | 18 | 2025 | 192 | 2.780 |
Why?
| | Infant, Newborn | 81 | 2026 | 6434 | 2.650 |
Why?
| | California | 40 | 2026 | 475 | 2.650 |
Why?
| | Maternal Exposure | 10 | 2021 | 213 | 2.640 |
Why?
| | Female | 245 | 2026 | 78376 | 2.540 |
Why?
| | Autoimmune Diseases | 9 | 2025 | 463 | 2.530 |
Why?
| | Antiphospholipid Syndrome | 3 | 2025 | 33 | 2.520 |
Why?
| | Abortion, Spontaneous | 12 | 2020 | 115 | 2.370 |
Why?
| | Infant, Small for Gestational Age | 11 | 2026 | 109 | 2.350 |
Why?
| | Mothers | 17 | 2025 | 775 | 2.030 |
Why?
| | Teratogens | 8 | 2025 | 20 | 1.920 |
Why?
| | Humans | 259 | 2026 | 144957 | 1.910 |
Why?
| | Gestational Age | 27 | 2026 | 975 | 1.710 |
Why?
| | Infant | 67 | 2025 | 10039 | 1.710 |
Why?
| | Pre-Eclampsia | 8 | 2026 | 205 | 1.690 |
Why?
| | Adult | 111 | 2026 | 40506 | 1.670 |
Why?
| | Influenza Vaccines | 6 | 2017 | 529 | 1.640 |
Why?
| | Antirheumatic Agents | 8 | 2025 | 304 | 1.630 |
Why?
| | Drug Hypersensitivity | 2 | 2026 | 90 | 1.600 |
Why?
| | Canada | 11 | 2025 | 428 | 1.440 |
Why?
| | Asthma | 9 | 2024 | 1768 | 1.330 |
Why?
| | Risk Factors | 52 | 2026 | 10792 | 1.330 |
Why?
| | Cohort Studies | 34 | 2026 | 5965 | 1.320 |
Why?
| | Lupus Erythematosus, Systemic | 6 | 2025 | 239 | 1.310 |
Why?
| | Depression | 10 | 2024 | 1559 | 1.280 |
Why?
| | Prospective Studies | 32 | 2026 | 7997 | 1.260 |
Why?
| | Analgesics, Non-Narcotic | 3 | 2026 | 124 | 1.200 |
Why?
| | Hypersensitivity | 4 | 2024 | 252 | 1.170 |
Why?
| | Ethanol | 16 | 2024 | 627 | 1.090 |
Why?
| | Child Development | 13 | 2026 | 484 | 1.070 |
Why?
| | Colitis, Ulcerative | 3 | 2025 | 148 | 1.070 |
Why?
| | Contraception | 5 | 2020 | 170 | 1.050 |
Why?
| | Lupus Nephritis | 2 | 2025 | 70 | 1.050 |
Why?
| | Research | 3 | 2021 | 431 | 1.050 |
Why?
| | Substance-Related Disorders | 9 | 2026 | 1094 | 1.050 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2019 | 68 | 1.050 |
Why?
| | Hemangioma | 2 | 2018 | 46 | 1.030 |
Why?
| | Indians, North American | 3 | 2019 | 647 | 1.030 |
Why?
| | Arthritis, Rheumatoid | 6 | 2023 | 1169 | 1.030 |
Why?
| | Young Adult | 51 | 2026 | 14126 | 1.010 |
Why?
| | Heart Defects, Congenital | 11 | 2026 | 914 | 0.990 |
Why?
| | Gastroschisis | 5 | 2018 | 32 | 0.980 |
Why?
| | Morning Sickness | 1 | 2026 | 3 | 0.970 |
Why?
| | Anti-Inflammatory Agents | 4 | 2025 | 475 | 0.930 |
Why?
| | Marijuana Use | 5 | 2024 | 213 | 0.930 |
Why?
| | Pregnancy Trimester, Second | 4 | 2018 | 82 | 0.930 |
Why?
| | Marijuana Abuse | 3 | 2026 | 211 | 0.930 |
Why?
| | Crohn Disease | 3 | 2025 | 260 | 0.920 |
Why?
| | Nausea | 1 | 2026 | 111 | 0.920 |
Why?
| | Antiemetics | 1 | 2026 | 49 | 0.920 |
Why?
| | Influenza A Virus, H1N1 Subtype | 4 | 2019 | 157 | 0.920 |
Why?
| | Pregnancy Complications, Infectious | 7 | 2026 | 428 | 0.910 |
Why?
| | Hyperemesis Gravidarum | 1 | 2025 | 6 | 0.910 |
Why?
| | Vomiting | 1 | 2026 | 130 | 0.900 |
Why?
| | Influenza, Human | 5 | 2019 | 617 | 0.900 |
Why?
| | Drug Therapy | 2 | 2016 | 80 | 0.890 |
Why?
| | Product Surveillance, Postmarketing | 4 | 2024 | 73 | 0.890 |
Why?
| | Sudden Infant Death | 2 | 2024 | 39 | 0.880 |
Why?
| | Case-Control Studies | 19 | 2024 | 3608 | 0.880 |
Why?
| | Child | 47 | 2026 | 22657 | 0.870 |
Why?
| | Birth Certificates | 1 | 2024 | 12 | 0.870 |
Why?
| | Psychotherapy, Brief | 2 | 2015 | 41 | 0.870 |
Why?
| | Gastrointestinal Agents | 1 | 2025 | 66 | 0.860 |
Why?
| | Glucocorticoids | 3 | 2018 | 535 | 0.860 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2024 | 389 | 0.850 |
Why?
| | Dietary Supplements | 8 | 2021 | 576 | 0.850 |
Why?
| | Hydroxychloroquine | 2 | 2023 | 63 | 0.820 |
Why?
| | Nicotine | 4 | 2026 | 332 | 0.810 |
Why?
| | Depressive Disorder | 4 | 2025 | 387 | 0.800 |
Why?
| | Crotonates | 2 | 2023 | 7 | 0.800 |
Why?
| | Toluidines | 2 | 2023 | 10 | 0.800 |
Why?
| | Hydroxybutyrates | 2 | 2023 | 15 | 0.800 |
Why?
| | Teratology | 3 | 2020 | 3 | 0.770 |
Why?
| | Cognition | 5 | 2025 | 1269 | 0.760 |
Why?
| | United States | 28 | 2026 | 15988 | 0.760 |
Why?
| | Plasmalogens | 1 | 2022 | 7 | 0.750 |
Why?
| | Acetaminophen | 4 | 2024 | 264 | 0.750 |
Why?
| | Strabismus | 1 | 2023 | 71 | 0.750 |
Why?
| | Birth Weight | 9 | 2026 | 522 | 0.750 |
Why?
| | Cannabis | 6 | 2025 | 509 | 0.730 |
Why?
| | Biological Products | 5 | 2026 | 252 | 0.730 |
Why?
| | Nitriles | 2 | 2023 | 205 | 0.720 |
Why?
| | Metformin | 1 | 2025 | 319 | 0.690 |
Why?
| | Prevalence | 11 | 2022 | 2836 | 0.680 |
Why?
| | Inflammatory Bowel Diseases | 4 | 2019 | 365 | 0.670 |
Why?
| | Child, Preschool | 25 | 2025 | 11799 | 0.670 |
Why?
| | Retrospective Studies | 30 | 2026 | 17101 | 0.660 |
Why?
| | Interviews as Topic | 6 | 2026 | 901 | 0.650 |
Why?
| | Prednisone | 2 | 2018 | 221 | 0.630 |
Why?
| | Research Design | 3 | 2025 | 1137 | 0.620 |
Why?
| | Dyssomnias | 1 | 2019 | 4 | 0.620 |
Why?
| | Medical Records | 2 | 2017 | 189 | 0.610 |
Why?
| | Adalimumab | 1 | 2019 | 55 | 0.600 |
Why?
| | Oseltamivir | 1 | 2019 | 15 | 0.600 |
Why?
| | Male | 68 | 2026 | 72406 | 0.600 |
Why?
| | Maternal-Fetal Exchange | 5 | 2022 | 169 | 0.580 |
Why?
| | Biological Specimen Banks | 1 | 2020 | 103 | 0.580 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 988 | 0.580 |
Why?
| | Arthritis | 1 | 2019 | 96 | 0.570 |
Why?
| | Referral and Consultation | 2 | 2015 | 853 | 0.570 |
Why?
| | Risk | 7 | 2019 | 911 | 0.570 |
Why?
| | Telephone | 2 | 2016 | 175 | 0.560 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2171 | 0.560 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 4 | 2026 | 428 | 0.550 |
Why?
| | Neonatal Screening | 3 | 2024 | 178 | 0.540 |
Why?
| | Immunosuppressive Agents | 2 | 2021 | 847 | 0.530 |
Why?
| | Infant Mortality | 4 | 2024 | 123 | 0.530 |
Why?
| | Central Nervous System Depressants | 4 | 2020 | 83 | 0.530 |
Why?
| | Substance Abuse Detection | 2 | 2018 | 106 | 0.520 |
Why?
| | Folic Acid | 2 | 2017 | 199 | 0.520 |
Why?
| | Maternal Age | 7 | 2025 | 126 | 0.520 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 1389 | 0.510 |
Why?
| | Ukraine | 14 | 2022 | 35 | 0.510 |
Why?
| | Probability | 1 | 2018 | 312 | 0.510 |
Why?
| | Patient Selection | 2 | 2021 | 719 | 0.510 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 158 | 0.510 |
Why?
| | Aminosalicylic Acids | 1 | 2016 | 9 | 0.500 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2025 | 257 | 0.500 |
Why?
| | Adolescent | 37 | 2023 | 22453 | 0.490 |
Why?
| | Odds Ratio | 7 | 2023 | 1077 | 0.480 |
Why?
| | Cannabinoids | 1 | 2018 | 182 | 0.470 |
Why?
| | Models, Statistical | 3 | 2018 | 682 | 0.470 |
Why?
| | Hydrocortisone | 1 | 2018 | 304 | 0.470 |
Why?
| | Public Health | 2 | 2019 | 566 | 0.470 |
Why?
| | Infant, Low Birth Weight | 5 | 2026 | 153 | 0.470 |
Why?
| | Cross-Sectional Studies | 11 | 2025 | 5872 | 0.470 |
Why?
| | Multiple Sclerosis | 2 | 2019 | 484 | 0.470 |
Why?
| | Motivational Interviewing | 1 | 2017 | 121 | 0.460 |
Why?
| | Aluminum Hydroxide | 1 | 2015 | 13 | 0.460 |
Why?
| | Risk Assessment | 11 | 2025 | 3676 | 0.450 |
Why?
| | Data Collection | 3 | 2023 | 635 | 0.450 |
Why?
| | Contraceptives, Oral | 1 | 2015 | 37 | 0.450 |
Why?
| | Lipid A | 1 | 2015 | 28 | 0.450 |
Why?
| | Decision Support Techniques | 3 | 2026 | 456 | 0.450 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1054 | 0.440 |
Why?
| | Registries | 7 | 2025 | 2385 | 0.440 |
Why?
| | Pain | 2 | 2022 | 782 | 0.440 |
Why?
| | Alaska Natives | 1 | 2017 | 149 | 0.440 |
Why?
| | Immunologic Factors | 2 | 2016 | 255 | 0.440 |
Why?
| | Medical Records Systems, Computerized | 1 | 2015 | 95 | 0.440 |
Why?
| | Fatty Acids | 2 | 2020 | 452 | 0.440 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.440 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2016 | 138 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.440 |
Why?
| | Anti-Asthmatic Agents | 4 | 2019 | 252 | 0.420 |
Why?
| | Physical Examination | 3 | 2023 | 240 | 0.420 |
Why?
| | Physician's Role | 2 | 2016 | 220 | 0.420 |
Why?
| | Antipsychotic Agents | 1 | 2016 | 214 | 0.420 |
Why?
| | Anti-Bacterial Agents | 3 | 2023 | 1915 | 0.410 |
Why?
| | Self Report | 2 | 2019 | 873 | 0.410 |
Why?
| | Dyspnea | 1 | 2016 | 251 | 0.410 |
Why?
| | Infant, Premature, Diseases | 3 | 2021 | 111 | 0.410 |
Why?
| | Preconception Care | 6 | 2025 | 50 | 0.400 |
Why?
| | Live Birth | 5 | 2022 | 68 | 0.400 |
Why?
| | Monte Carlo Method | 1 | 2014 | 155 | 0.400 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1563 | 0.390 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2021 | 2032 | 0.390 |
Why?
| | Biomarkers | 9 | 2024 | 4275 | 0.380 |
Why?
| | Neuropsychological Tests | 7 | 2023 | 1137 | 0.380 |
Why?
| | Pregnancy Complications, Cardiovascular | 3 | 2024 | 83 | 0.380 |
Why?
| | Poverty | 5 | 2020 | 530 | 0.380 |
Why?
| | Vaccination | 5 | 2025 | 1423 | 0.370 |
Why?
| | Adrenal Cortex Hormones | 3 | 2026 | 479 | 0.370 |
Why?
| | Socioeconomic Factors | 8 | 2024 | 1327 | 0.370 |
Why?
| | Neurodevelopmental Disorders | 5 | 2020 | 227 | 0.360 |
Why?
| | Propensity Score | 1 | 2014 | 367 | 0.360 |
Why?
| | Counseling | 1 | 2015 | 408 | 0.350 |
Why?
| | Developmental Disabilities | 4 | 2024 | 281 | 0.350 |
Why?
| | Severity of Illness Index | 9 | 2021 | 2925 | 0.350 |
Why?
| | Papillomavirus Vaccines | 1 | 2015 | 297 | 0.340 |
Why?
| | Logistic Models | 9 | 2020 | 2119 | 0.340 |
Why?
| | Pandemics | 1 | 2020 | 1695 | 0.340 |
Why?
| | Child Behavior | 3 | 2026 | 236 | 0.340 |
Why?
| | Fetal Growth Retardation | 5 | 2023 | 587 | 0.340 |
Why?
| | Environmental Pollutants | 2 | 2025 | 167 | 0.330 |
Why?
| | Prenatal Care | 6 | 2019 | 307 | 0.330 |
Why?
| | Critical Pathways | 4 | 2019 | 108 | 0.330 |
Why?
| | Electronic Health Records | 2 | 2017 | 1177 | 0.320 |
Why?
| | Etanercept | 2 | 2022 | 60 | 0.320 |
Why?
| | Maternal Behavior | 3 | 2020 | 84 | 0.320 |
Why?
| | Decision Making | 1 | 2018 | 980 | 0.320 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2025 | 81 | 0.320 |
Why?
| | Placenta | 5 | 2023 | 780 | 0.310 |
Why?
| | Population Surveillance | 4 | 2019 | 485 | 0.310 |
Why?
| | MicroRNAs | 3 | 2023 | 701 | 0.310 |
Why?
| | Lipid Metabolism | 1 | 2013 | 528 | 0.300 |
Why?
| | Fertility Preservation | 2 | 2020 | 53 | 0.300 |
Why?
| | Likelihood Functions | 3 | 2018 | 143 | 0.300 |
Why?
| | Mobile Applications | 2 | 2022 | 196 | 0.290 |
Why?
| | Environmental Exposure | 4 | 2025 | 590 | 0.290 |
Why?
| | Craniofacial Abnormalities | 1 | 2009 | 76 | 0.290 |
Why?
| | Prenatal Diagnosis | 4 | 2018 | 195 | 0.290 |
Why?
| | Musculoskeletal Diseases | 2 | 2020 | 90 | 0.280 |
Why?
| | Drug Labeling | 2 | 2020 | 37 | 0.280 |
Why?
| | Gastroenterology | 3 | 2019 | 189 | 0.280 |
Why?
| | Problem Behavior | 2 | 2020 | 102 | 0.280 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 917 | 0.280 |
Why?
| | Frontal Lobe | 1 | 2009 | 160 | 0.270 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1325 | 0.270 |
Why?
| | Patient Care Planning | 2 | 2019 | 170 | 0.260 |
Why?
| | Paternity | 1 | 2007 | 4 | 0.260 |
Why?
| | Oligosaccharides | 2 | 2024 | 60 | 0.260 |
Why?
| | Lipids | 2 | 2025 | 710 | 0.250 |
Why?
| | alpha-Fetoproteins | 3 | 2016 | 40 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2365 | 0.240 |
Why?
| | Dicyclomine | 1 | 2026 | 1 | 0.240 |
Why?
| | Doxylamine | 1 | 2026 | 3 | 0.240 |
Why?
| | Infant Death | 2 | 2023 | 9 | 0.240 |
Why?
| | Anxiety | 3 | 2024 | 1110 | 0.240 |
Why?
| | Maternal Health | 4 | 2024 | 52 | 0.240 |
Why?
| | Hospitalization | 6 | 2024 | 2434 | 0.240 |
Why?
| | Pyridoxine | 1 | 2026 | 37 | 0.240 |
Why?
| | Risk Evaluation and Mitigation | 1 | 2025 | 1 | 0.230 |
Why?
| | Antiviral Agents | 2 | 2024 | 768 | 0.230 |
Why?
| | Anti-Allergic Agents | 1 | 2006 | 40 | 0.230 |
Why?
| | Cognitive Science | 1 | 2025 | 4 | 0.230 |
Why?
| | C-Peptide | 2 | 2018 | 189 | 0.230 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2025 | 16 | 0.230 |
Why?
| | Endocrine Disruptors | 1 | 2025 | 45 | 0.230 |
Why?
| | Reproductive Health | 3 | 2022 | 91 | 0.220 |
Why?
| | Infant, Premature | 5 | 2026 | 611 | 0.220 |
Why?
| | Reproduction | 2 | 2025 | 207 | 0.220 |
Why?
| | Twins | 1 | 2006 | 156 | 0.220 |
Why?
| | Mammary Glands, Human | 1 | 2025 | 67 | 0.220 |
Why?
| | Milk Proteins | 1 | 2025 | 35 | 0.220 |
Why?
| | Child Behavior Disorders | 1 | 2026 | 118 | 0.220 |
Why?
| | Pregnancy Trimester, First | 3 | 2026 | 136 | 0.220 |
Why?
| | Prescription Drugs | 2 | 2017 | 111 | 0.220 |
Why?
| | Neuropsychology | 1 | 2025 | 42 | 0.220 |
Why?
| | Unemployment | 1 | 2024 | 42 | 0.220 |
Why?
| | Drug Combinations | 1 | 2026 | 392 | 0.220 |
Why?
| | Carbohydrates | 1 | 2025 | 66 | 0.210 |
Why?
| | Genetic Diseases, Inborn | 1 | 2024 | 44 | 0.210 |
Why?
| | Mammary Glands, Animal | 1 | 2025 | 128 | 0.210 |
Why?
| | Healthcare Disparities | 2 | 2024 | 728 | 0.210 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2018 | 2584 | 0.210 |
Why?
| | Face | 1 | 2026 | 174 | 0.210 |
Why?
| | Protective Factors | 1 | 2024 | 99 | 0.210 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2024 | 44 | 0.210 |
Why?
| | Checklist | 1 | 2025 | 108 | 0.210 |
Why?
| | Medical Record Linkage | 1 | 2024 | 68 | 0.210 |
Why?
| | Perinatal Mortality | 1 | 2024 | 21 | 0.210 |
Why?
| | Apolipoproteins E | 1 | 2024 | 94 | 0.200 |
Why?
| | Medicaid | 2 | 2020 | 462 | 0.200 |
Why?
| | Heart Rate | 4 | 2022 | 855 | 0.200 |
Why?
| | Social Class | 3 | 2020 | 268 | 0.200 |
Why?
| | Fingolimod Hydrochloride | 1 | 2023 | 39 | 0.200 |
Why?
| | Eclampsia | 2 | 2021 | 6 | 0.200 |
Why?
| | Retinopathy of Prematurity | 1 | 2026 | 179 | 0.200 |
Why?
| | Penicillins | 1 | 2023 | 61 | 0.200 |
Why?
| | Pleurisy | 1 | 2023 | 6 | 0.200 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2024 | 47 | 0.200 |
Why?
| | Diet | 3 | 2017 | 1275 | 0.200 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 86 | 0.190 |
Why?
| | Alanine | 1 | 2024 | 171 | 0.190 |
Why?
| | Databases, Factual | 6 | 2020 | 1486 | 0.190 |
Why?
| | Longitudinal Studies | 8 | 2026 | 2947 | 0.190 |
Why?
| | Follow-Up Studies | 7 | 2021 | 5417 | 0.190 |
Why?
| | Linear Models | 3 | 2023 | 854 | 0.190 |
Why?
| | Wireless Technology | 1 | 2022 | 18 | 0.190 |
Why?
| | Hypothermia, Induced | 1 | 2024 | 96 | 0.190 |
Why?
| | Reaction Time | 2 | 2021 | 438 | 0.190 |
Why?
| | Fetal Death | 1 | 2002 | 58 | 0.190 |
Why?
| | Antibodies, Viral | 2 | 2024 | 672 | 0.190 |
Why?
| | Saliva | 1 | 2024 | 249 | 0.190 |
Why?
| | Gaucher Disease | 1 | 2022 | 4 | 0.180 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2022 | 28 | 0.180 |
Why?
| | Stress, Psychological | 2 | 2024 | 1153 | 0.180 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.180 |
Why?
| | Mastitis | 1 | 2022 | 6 | 0.180 |
Why?
| | Fenfluramine | 1 | 2002 | 17 | 0.180 |
Why?
| | Appetite Depressants | 1 | 2002 | 19 | 0.180 |
Why?
| | Disease Management | 3 | 2021 | 647 | 0.180 |
Why?
| | Phentermine | 1 | 2002 | 14 | 0.180 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 17 | 0.180 |
Why?
| | Universities | 1 | 2024 | 452 | 0.180 |
Why?
| | Isoxazoles | 1 | 2002 | 54 | 0.180 |
Why?
| | United States Food and Drug Administration | 3 | 2020 | 205 | 0.180 |
Why?
| | Intestinal Mucosa | 2 | 2025 | 676 | 0.180 |
Why?
| | Surveys and Questionnaires | 10 | 2026 | 6053 | 0.180 |
Why?
| | Epigenesis, Genetic | 2 | 2024 | 685 | 0.180 |
Why?
| | Choline | 3 | 2019 | 136 | 0.180 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 183 | 0.170 |
Why?
| | Fluorocarbons | 1 | 2023 | 143 | 0.170 |
Why?
| | Central Nervous System Agents | 1 | 2021 | 7 | 0.170 |
Why?
| | Rheumatology | 2 | 2020 | 133 | 0.170 |
Why?
| | Delphi Technique | 4 | 2025 | 331 | 0.170 |
Why?
| | Fetal Diseases | 2 | 2018 | 191 | 0.170 |
Why?
| | Paternal Exposure | 1 | 2021 | 1 | 0.170 |
Why?
| | Discrimination Learning | 1 | 2021 | 54 | 0.170 |
Why?
| | Cannabidiol | 1 | 2023 | 136 | 0.170 |
Why?
| | Middle Aged | 9 | 2020 | 35928 | 0.170 |
Why?
| | Biological Factors | 1 | 2021 | 39 | 0.170 |
Why?
| | Pilot Projects | 3 | 2021 | 1890 | 0.170 |
Why?
| | Fever | 1 | 2002 | 312 | 0.170 |
Why?
| | Infant Behavior | 1 | 2021 | 26 | 0.170 |
Why?
| | Psychotropic Drugs | 1 | 2021 | 77 | 0.160 |
Why?
| | Immune System Diseases | 1 | 2021 | 39 | 0.160 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 28 | 0.160 |
Why?
| | Administration, Oral | 2 | 2026 | 848 | 0.160 |
Why?
| | Psychomotor Performance | 3 | 2020 | 328 | 0.160 |
Why?
| | Teratogenesis | 2 | 2018 | 2 | 0.160 |
Why?
| | Disruptive, Impulse Control, and Conduct Disorders | 1 | 2020 | 10 | 0.160 |
Why?
| | Alemtuzumab | 1 | 2020 | 15 | 0.160 |
Why?
| | Multivariate Analysis | 3 | 2018 | 1540 | 0.160 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2021 | 39 | 0.160 |
Why?
| | Hypertension | 2 | 2019 | 1264 | 0.160 |
Why?
| | Term Birth | 2 | 2018 | 25 | 0.160 |
Why?
| | Mental Health | 2 | 2024 | 792 | 0.160 |
Why?
| | Abruptio Placentae | 1 | 2019 | 6 | 0.160 |
Why?
| | Brain | 3 | 2024 | 2941 | 0.160 |
Why?
| | Pediatrics | 2 | 2016 | 1115 | 0.150 |
Why?
| | Marriage | 1 | 2021 | 122 | 0.150 |
Why?
| | Circadian Rhythm | 1 | 2024 | 514 | 0.150 |
Why?
| | Postpartum Hemorrhage | 1 | 2020 | 28 | 0.150 |
Why?
| | Southwestern United States | 1 | 2019 | 95 | 0.150 |
Why?
| | Pro-Opiomelanocortin | 1 | 2019 | 20 | 0.150 |
Why?
| | Micronutrients | 2 | 2021 | 96 | 0.150 |
Why?
| | Health Personnel | 1 | 2026 | 748 | 0.150 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 1999 | 44 | 0.150 |
Why?
| | Behavioral Symptoms | 1 | 2019 | 43 | 0.150 |
Why?
| | Weight Gain | 2 | 2022 | 559 | 0.150 |
Why?
| | Geographic Mapping | 1 | 2019 | 29 | 0.150 |
Why?
| | Period Circadian Proteins | 1 | 2019 | 33 | 0.150 |
Why?
| | Alcoholism | 3 | 2021 | 817 | 0.150 |
Why?
| | Stillbirth | 3 | 2026 | 77 | 0.150 |
Why?
| | Fluoxetine | 1 | 1999 | 54 | 0.150 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 412 | 0.150 |
Why?
| | Prognosis | 3 | 2017 | 4293 | 0.150 |
Why?
| | Cities | 1 | 2019 | 143 | 0.150 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2019 | 43 | 0.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 82 | 0.150 |
Why?
| | Zika Virus | 1 | 2020 | 132 | 0.150 |
Why?
| | Mood Disorders | 1 | 2020 | 140 | 0.150 |
Why?
| | Placentation | 1 | 2019 | 53 | 0.140 |
Why?
| | Family | 1 | 2023 | 679 | 0.140 |
Why?
| | Memory Disorders | 1 | 2020 | 194 | 0.140 |
Why?
| | Circulating MicroRNA | 1 | 2019 | 26 | 0.140 |
Why?
| | Postpartum Period | 2 | 2016 | 365 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1129 | 0.140 |
Why?
| | Pain Measurement | 1 | 2021 | 555 | 0.140 |
Why?
| | Certolizumab Pegol | 1 | 2018 | 5 | 0.140 |
Why?
| | Executive Function | 2 | 2021 | 461 | 0.140 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 113 | 0.140 |
Why?
| | Immune System | 1 | 2020 | 179 | 0.140 |
Why?
| | Algorithms | 4 | 2022 | 1839 | 0.140 |
Why?
| | Vaccines | 1 | 2023 | 389 | 0.140 |
Why?
| | Intellectual Disability | 1 | 2020 | 175 | 0.140 |
Why?
| | Heart Block | 1 | 2018 | 40 | 0.140 |
Why?
| | Clinical Competence | 1 | 2006 | 1244 | 0.140 |
Why?
| | Organic Chemicals | 1 | 2019 | 127 | 0.140 |
Why?
| | Fetal Macrosomia | 1 | 2018 | 62 | 0.140 |
Why?
| | Zika Virus Infection | 1 | 2020 | 168 | 0.140 |
Why?
| | Food Supply | 2 | 2017 | 90 | 0.140 |
Why?
| | Precision Medicine | 1 | 2022 | 458 | 0.140 |
Why?
| | Selection Bias | 1 | 2018 | 38 | 0.130 |
Why?
| | Peptides | 1 | 2024 | 998 | 0.130 |
Why?
| | Chorioamnionitis | 1 | 2018 | 45 | 0.130 |
Why?
| | Electrocardiography | 2 | 2022 | 663 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 299 | 0.130 |
Why?
| | Vasculitis | 1 | 2018 | 69 | 0.130 |
Why?
| | Benzodiazepines | 1 | 2019 | 168 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 199 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3415 | 0.130 |
Why?
| | Fertilization in Vitro | 1 | 2018 | 92 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 359 | 0.130 |
Why?
| | Alaska | 1 | 2017 | 83 | 0.130 |
Why?
| | Albuterol | 1 | 2017 | 73 | 0.130 |
Why?
| | Vaccines, Inactivated | 1 | 2017 | 70 | 0.130 |
Why?
| | Regression Analysis | 1 | 2020 | 1003 | 0.130 |
Why?
| | Hemangioma, Capillary | 1 | 2017 | 14 | 0.130 |
Why?
| | Cocaine-Related Disorders | 1 | 2018 | 132 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1407 | 0.130 |
Why?
| | Maternal Health Services | 1 | 2019 | 102 | 0.130 |
Why?
| | Placenta Diseases | 1 | 2017 | 19 | 0.130 |
Why?
| | Vascular Neoplasms | 1 | 2017 | 18 | 0.130 |
Why?
| | Ibuprofen | 1 | 2017 | 84 | 0.130 |
Why?
| | Early Medical Intervention | 1 | 2017 | 61 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Pneumonia | 1 | 2023 | 631 | 0.130 |
Why?
| | Dyslipidemias | 1 | 2018 | 182 | 0.130 |
Why?
| | Air Pollution, Radioactive | 1 | 2016 | 3 | 0.130 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2017 | 90 | 0.130 |
Why?
| | Cesium Radioisotopes | 1 | 2016 | 4 | 0.130 |
Why?
| | Public Health Surveillance | 1 | 2017 | 83 | 0.130 |
Why?
| | Chernobyl Nuclear Accident | 1 | 2016 | 5 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 2019 | 216 | 0.120 |
Why?
| | Analgesics, Opioid | 2 | 2026 | 1143 | 0.120 |
Why?
| | Sepsis | 1 | 2023 | 641 | 0.120 |
Why?
| | Treatment Outcome | 5 | 2019 | 11695 | 0.120 |
Why?
| | Fetus | 3 | 2018 | 803 | 0.120 |
Why?
| | Nonprescription Drugs | 1 | 2017 | 65 | 0.120 |
Why?
| | Cost of Illness | 1 | 2019 | 321 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2019 | 251 | 0.120 |
Why?
| | Overweight | 2 | 2022 | 609 | 0.120 |
Why?
| | Insurance Coverage | 1 | 2018 | 239 | 0.120 |
Why?
| | Habituation, Psychophysiologic | 1 | 2016 | 58 | 0.120 |
Why?
| | Growth | 1 | 2016 | 49 | 0.120 |
Why?
| | Patient Discharge | 1 | 2022 | 983 | 0.120 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2017 | 120 | 0.120 |
Why?
| | Cytokines | 3 | 2020 | 2065 | 0.120 |
Why?
| | Social Determinants of Health | 1 | 2020 | 301 | 0.120 |
Why?
| | Republic of Korea | 1 | 2015 | 42 | 0.120 |
Why?
| | Medication Therapy Management | 1 | 2016 | 73 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 284 | 0.110 |
Why?
| | C-Reactive Protein | 1 | 2018 | 417 | 0.110 |
Why?
| | Mental Processes | 1 | 2015 | 38 | 0.110 |
Why?
| | Indians, South American | 1 | 2015 | 23 | 0.110 |
Why?
| | Age Factors | 3 | 2018 | 3335 | 0.110 |
Why?
| | Food Services | 1 | 2015 | 21 | 0.110 |
Why?
| | Body Mass Index | 3 | 2022 | 2438 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2025 | 1158 | 0.110 |
Why?
| | Underage Drinking | 1 | 2015 | 22 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2018 | 321 | 0.110 |
Why?
| | Echocardiography | 1 | 2018 | 652 | 0.110 |
Why?
| | Information Services | 3 | 2020 | 46 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2026 | 1416 | 0.110 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 186 | 0.110 |
Why?
| | Genetic Testing | 3 | 2024 | 482 | 0.110 |
Why?
| | Drug Utilization | 1 | 2015 | 167 | 0.110 |
Why?
| | Animals | 11 | 2025 | 38109 | 0.110 |
Why?
| | Microbiota | 1 | 2022 | 781 | 0.110 |
Why?
| | Mental Recall | 1 | 2016 | 222 | 0.110 |
Why?
| | Therapy, Computer-Assisted | 1 | 2015 | 64 | 0.110 |
Why?
| | Survival Analysis | 1 | 2017 | 1385 | 0.100 |
Why?
| | Ultrasonography, Prenatal | 1 | 2016 | 294 | 0.100 |
Why?
| | United Kingdom | 1 | 2015 | 338 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 557 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2017 | 378 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 338 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2017 | 266 | 0.100 |
Why?
| | Obesity | 4 | 2022 | 3082 | 0.100 |
Why?
| | Microcephaly | 2 | 2016 | 103 | 0.100 |
Why?
| | Computer Simulation | 1 | 2018 | 1026 | 0.100 |
Why?
| | Nutritional Status | 1 | 2016 | 354 | 0.100 |
Why?
| | Immunization | 1 | 2015 | 374 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2021 | 2832 | 0.100 |
Why?
| | Epidemiological Monitoring | 1 | 2013 | 69 | 0.100 |
Why?
| | Pregnancy Trimesters | 3 | 2018 | 20 | 0.100 |
Why?
| | Energy Intake | 1 | 2016 | 500 | 0.100 |
Why?
| | Smoking | 1 | 2020 | 1472 | 0.090 |
Why?
| | Motivation | 1 | 2017 | 610 | 0.090 |
Why?
| | Heart | 1 | 2016 | 636 | 0.090 |
Why?
| | Lung Diseases | 1 | 2019 | 787 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1322 | 0.090 |
Why?
| | Risk-Taking | 1 | 2015 | 328 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 1990 | 0.090 |
Why?
| | Linoleic Acid | 1 | 2012 | 44 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 477 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 886 | 0.080 |
Why?
| | Recurrence | 3 | 2020 | 1135 | 0.080 |
Why?
| | Fetal Blood | 2 | 2023 | 342 | 0.080 |
Why?
| | Incidence | 3 | 2026 | 2883 | 0.080 |
Why?
| | Health Surveys | 1 | 2012 | 518 | 0.080 |
Why?
| | Autoantibodies | 1 | 2018 | 1504 | 0.080 |
Why?
| | Dietary Fats | 1 | 2012 | 315 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 966 | 0.080 |
Why?
| | Cephalometry | 1 | 2009 | 30 | 0.070 |
Why?
| | Comorbidity | 3 | 2020 | 1660 | 0.070 |
Why?
| | Time Factors | 3 | 2018 | 7183 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1358 | 0.070 |
Why?
| | Mice | 5 | 2025 | 18365 | 0.070 |
Why?
| | Stakeholder Participation | 2 | 2019 | 84 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1048 | 0.070 |
Why?
| | Liver | 1 | 2017 | 1888 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5997 | 0.070 |
Why?
| | Patient Compliance | 2 | 2016 | 589 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1291 | 0.060 |
Why?
| | Phenotype | 1 | 2015 | 3164 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1172 | 0.060 |
Why?
| | Early Diagnosis | 2 | 2019 | 249 | 0.060 |
Why?
| | Sex Characteristics | 2 | 2016 | 791 | 0.060 |
Why?
| | Karyotyping | 1 | 2006 | 106 | 0.060 |
Why?
| | Transcriptome | 2 | 2023 | 1046 | 0.060 |
Why?
| | Educational Status | 2 | 2018 | 467 | 0.060 |
Why?
| | Halogenated Diphenyl Ethers | 1 | 2025 | 7 | 0.060 |
Why?
| | Nutrition Surveys | 2 | 2019 | 282 | 0.060 |
Why?
| | Theophylline | 1 | 2006 | 41 | 0.060 |
Why?
| | Latin America | 1 | 2006 | 94 | 0.060 |
Why?
| | Temperance | 1 | 2005 | 20 | 0.060 |
Why?
| | Parabens | 1 | 2025 | 15 | 0.060 |
Why?
| | Diet Surveys | 1 | 2006 | 91 | 0.060 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2025 | 23 | 0.060 |
Why?
| | Isotretinoin | 1 | 2005 | 26 | 0.060 |
Why?
| | Multilingualism | 1 | 2005 | 29 | 0.060 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 1 | 2025 | 29 | 0.060 |
Why?
| | Social Welfare | 1 | 2005 | 27 | 0.060 |
Why?
| | Growth Disorders | 1 | 2006 | 86 | 0.060 |
Why?
| | Adrenergic beta-Agonists | 1 | 2006 | 93 | 0.060 |
Why?
| | Acculturation | 1 | 2005 | 54 | 0.060 |
Why?
| | Alcoholic Beverages | 1 | 2005 | 31 | 0.060 |
Why?
| | Pesticides | 1 | 2025 | 63 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2507 | 0.060 |
Why?
| | Dermatologic Agents | 1 | 2005 | 68 | 0.060 |
Why?
| | Colorado | 1 | 2015 | 4564 | 0.050 |
Why?
| | Phenols | 1 | 2025 | 114 | 0.050 |
Why?
| | CLOCK Proteins | 1 | 2024 | 9 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2021 | 2540 | 0.050 |
Why?
| | Transient Tachypnea of the Newborn | 1 | 2024 | 1 | 0.050 |
Why?
| | Carnitine | 1 | 2024 | 90 | 0.050 |
Why?
| | Glucosyltransferases | 1 | 2023 | 4 | 0.050 |
Why?
| | Perinatal Death | 1 | 2024 | 26 | 0.050 |
Why?
| | Circadian Clocks | 1 | 2024 | 59 | 0.050 |
Why?
| | Mutation | 1 | 2015 | 4099 | 0.050 |
Why?
| | Allergy and Immunology | 1 | 2024 | 42 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2025 | 331 | 0.050 |
Why?
| | Urinary Tract Infections | 2 | 2016 | 203 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2118 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 489 | 0.050 |
Why?
| | Haplotypes | 1 | 2024 | 490 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2025 | 372 | 0.050 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2024 | 106 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2024 | 2609 | 0.050 |
Why?
| | Tooth, Deciduous | 1 | 2022 | 19 | 0.050 |
Why?
| | Infant Health | 1 | 2022 | 25 | 0.050 |
Why?
| | Craniosynostoses | 1 | 2003 | 68 | 0.050 |
Why?
| | Glucosylceramidase | 1 | 2022 | 5 | 0.050 |
Why?
| | Causality | 1 | 2023 | 126 | 0.050 |
Why?
| | Enzyme Replacement Therapy | 1 | 2022 | 15 | 0.050 |
Why?
| | Focus Groups | 1 | 2025 | 573 | 0.050 |
Why?
| | Genome, Human | 1 | 2024 | 422 | 0.050 |
Why?
| | Bias | 1 | 2023 | 202 | 0.050 |
Why?
| | Endocardial Cushions | 1 | 2022 | 7 | 0.050 |
Why?
| | Adenosine | 1 | 2024 | 255 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2024 | 598 | 0.040 |
Why?
| | Learning | 2 | 2016 | 452 | 0.040 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2025 | 370 | 0.040 |
Why?
| | Neural Tube Defects | 2 | 2016 | 65 | 0.040 |
Why?
| | Rats | 2 | 2021 | 5614 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 279 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 214 | 0.040 |
Why?
| | Mercaptopurine | 1 | 2020 | 15 | 0.040 |
Why?
| | Nervous System | 1 | 2021 | 70 | 0.040 |
Why?
| | Organizations | 1 | 2020 | 27 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 49 | 0.040 |
Why?
| | Cell Movement | 1 | 2025 | 965 | 0.040 |
Why?
| | Hysterectomy | 1 | 2021 | 138 | 0.040 |
Why?
| | Chromosomes, Human, Y | 1 | 2020 | 37 | 0.040 |
Why?
| | ROC Curve | 1 | 2022 | 615 | 0.040 |
Why?
| | Cesarean Section | 1 | 2022 | 224 | 0.040 |
Why?
| | Chromosomes, Human, X | 1 | 2020 | 76 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 454 | 0.040 |
Why?
| | Truncus Arteriosus, Persistent | 1 | 2019 | 7 | 0.040 |
Why?
| | Sex Factors | 1 | 2026 | 2114 | 0.040 |
Why?
| | Lipotropic Agents | 1 | 2019 | 5 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2020 | 115 | 0.040 |
Why?
| | Halogenation | 1 | 2019 | 23 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2019 | 18 | 0.040 |
Why?
| | Transposition of Great Vessels | 1 | 2019 | 41 | 0.040 |
Why?
| | Communication Disorders | 1 | 2019 | 13 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 131 | 0.040 |
Why?
| | Norway | 1 | 2019 | 45 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 62 | 0.040 |
Why?
| | Motor Disorders | 1 | 2019 | 17 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2018 | 23 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2021 | 361 | 0.040 |
Why?
| | Postnatal Care | 1 | 2019 | 72 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2021 | 271 | 0.040 |
Why?
| | Geography | 1 | 2019 | 203 | 0.030 |
Why?
| | Inpatients | 1 | 2023 | 546 | 0.030 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.030 |
Why?
| | Antibodies, Antinuclear | 1 | 2018 | 62 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2021 | 346 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2019 | 191 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 893 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 2018 | 39 | 0.030 |
Why?
| | Safety | 2 | 2014 | 356 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2026 | 1186 | 0.030 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 22 | 0.030 |
Why?
| | Sampling Studies | 1 | 2018 | 99 | 0.030 |
Why?
| | RNA, Viral | 1 | 2022 | 688 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 102 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 197 | 0.030 |
Why?
| | Thrombosis | 1 | 2021 | 393 | 0.030 |
Why?
| | Infant, Postmature | 1 | 2017 | 1 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 129 | 0.030 |
Why?
| | Chemokines | 1 | 2018 | 218 | 0.030 |
Why?
| | Fertilization | 1 | 2017 | 44 | 0.030 |
Why?
| | Food Assistance | 1 | 2017 | 34 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2020 | 422 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 220 | 0.030 |
Why?
| | Microphthalmos | 1 | 2016 | 2 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2018 | 160 | 0.030 |
Why?
| | Forecasting | 1 | 2019 | 391 | 0.030 |
Why?
| | Obstetrics | 1 | 2019 | 175 | 0.030 |
Why?
| | Sweden | 1 | 2017 | 111 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 427 | 0.030 |
Why?
| | Parity | 1 | 2017 | 109 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2017 | 37 | 0.030 |
Why?
| | Metabolomics | 1 | 2022 | 727 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2020 | 373 | 0.030 |
Why?
| | Birth Intervals | 1 | 2016 | 23 | 0.030 |
Why?
| | Fruit | 1 | 2017 | 152 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2147 | 0.030 |
Why?
| | Trophoblasts | 1 | 2019 | 216 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 292 | 0.030 |
Why?
| | Vegetables | 1 | 2017 | 170 | 0.030 |
Why?
| | Nutrition Assessment | 1 | 2016 | 92 | 0.030 |
Why?
| | Sunlight | 1 | 2017 | 78 | 0.030 |
Why?
| | Perinatal Care | 1 | 2016 | 62 | 0.030 |
Why?
| | Sarcosine | 1 | 2015 | 10 | 0.030 |
Why?
| | Insurance, Health | 1 | 2018 | 303 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 892 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 376 | 0.030 |
Why?
| | Bacteria | 1 | 2022 | 889 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1268 | 0.030 |
Why?
| | Beijing | 1 | 2015 | 2 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2017 | 221 | 0.030 |
Why?
| | Photic Stimulation | 1 | 2016 | 264 | 0.030 |
Why?
| | Personality Disorders | 1 | 2016 | 79 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2017 | 310 | 0.030 |
Why?
| | Fetal Development | 1 | 2018 | 299 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2016 | 334 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2017 | 373 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 189 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2015 | 333 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2017 | 8279 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2019 | 489 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 983 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 683 | 0.030 |
Why?
| | Memory | 1 | 2016 | 296 | 0.030 |
Why?
| | Seasons | 1 | 2017 | 556 | 0.030 |
Why?
| | Communication | 1 | 2020 | 967 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1077 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1813 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4569 | 0.020 |
Why?
| | Vitamin D | 1 | 2017 | 400 | 0.020 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 166 | 0.020 |
Why?
| | Patient Care Team | 1 | 2019 | 689 | 0.020 |
Why?
| | Virus Diseases | 1 | 2015 | 216 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 557 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2017 | 1217 | 0.020 |
Why?
| | Schizophrenia | 1 | 2016 | 446 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1495 | 0.020 |
Why?
| | Schools | 1 | 2015 | 453 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2029 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2313 | 0.020 |
Why?
| | Health Behavior | 1 | 2017 | 786 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2499 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3550 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1721 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1822 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2880 | 0.020 |
Why?
| | Self Disclosure | 1 | 2008 | 62 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1098 | 0.020 |
Why?
| | Aged | 2 | 2017 | 25947 | 0.020 |
Why?
| | Pregnancy Tests | 1 | 2005 | 10 | 0.010 |
Why?
| | Hotlines | 1 | 2004 | 32 | 0.010 |
Why?
| | Information Dissemination | 1 | 2006 | 223 | 0.010 |
Why?
| | Occipital Bone | 1 | 2003 | 18 | 0.010 |
Why?
| | Supine Position | 1 | 2003 | 37 | 0.010 |
Why?
| | Child Language | 1 | 2003 | 21 | 0.010 |
Why?
| | Skull | 1 | 2003 | 158 | 0.010 |
Why?
| | Radiography | 1 | 2003 | 845 | 0.010 |
Why?
| | Sleep | 1 | 2003 | 901 | 0.010 |
Why?
|
|
Chambers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|